2 min read
RAPS US Convergence
Meet Veristat at RAPS US Convergence 2025
Where Regulatory Excellence Meets Real-World Impact
Veristat is delighted...
1 min read
Podcast: Orphan Drug Designations and Orphan Subsets
Sponsors developing drugs or biologics intended to prevent, diagnose, or treat a rare disease or condition should consider applying for the Orphan Drug Designation (ODD) program with the FDA. The FDA’s Orphan Drug Designation program is meant to encourage the development of therapies for rare diseases and provides incentives for orphan products including exemption from user fees, a potential for 7 years of market exclusivity, and tax credits for some clinical trials.
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies (ART) Podcast to learn more about Orphan Drug Designation classification and the strategic use of orphan subsets in study design.
Learning Points
- Orphan Drug Designation criteria
- What makes a subgroup of a disease ‘inappropriate’ or ‘scientifically justified’ for orphan drug designation?
- Scenario examples of how to determine a ‘scientifically justified' orphan subgroup.
Meet Veristat. Learn More.
Get the Latest News
Categories
- Regulatory Consulting (125)
- Regulatory Submissions (120)
- Clinical Trial Regulations (110)
- COVID-19 (46)
- Strategic Consulting (35)
- Clinical Trials (24)
- Life At Veristat (21)
- Events (16)
- Oncology (13)
- Success Stories (13)
- Project Management (11)
- Decentralized Trials/Virtual Trials (9)
- Medical Writing (9)
- Clinical Operations/Monitoring (8)
- Full-Service (7)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Neurology/CNS (1)
- Rare Diseases (1)
5 min read
Clinical Outsourcing Group CRO Summit - Bay Area
Aug 28, 2025 Veristat Events